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Promotion of appropriate and safe drugs in children is the need of the hour globally. Pediatric population by itself is a spectrum
of diﬀerent physiologies with signiﬁcant variation in pharmacodynamics and pharmacokinetics. Unfortunately, 50–90% of drugs
used in children today have never been actually studied in this population, and the results of drug studies done in adults are often
extrapolated for use in children. Many medicines in pediatrics are oﬀ label or unlicensed. There is a spurt in drug resistance due to
the overzealous prescription of antimicrobials not indicated, such as, using inadequate dosage or duration of drug regime leading
to partially treated infections, using the wrong antimicrobial due to ignorance of causative organism, and ﬁnally using indigenous,
irrational combinations. Availability of properly labeled and safe pediatric formulations, regular audit by pharmacists, judicious
prescriptions, proper counseling about drug administration, surveillance of adverse eﬀects, and pediatric drug trials can be the
best possible interventions to oﬀer appropriate medicines to children and thereby save millions of lives.
1.Introduction
Globally nearly nine million children under ﬁve years of
age die every year, with pneumonia, diarrhea, and neonatal
causes being the major killers [1]. Many of these conditions
could be treated with safe, eﬀective medicines. On the
other hand, irrational use of the available drugs has led
to adverse drug reactions and drug resistance to the usual
pathogens and infections by unusual organisms. Promotion
of appropriate and safe drugs in children is the need of the
hour globally.
2. Child: Not aMiniatureAdult
Signiﬁcant changes in the pharmacokinetics and pharma-
codynamics occur as preterm infants mature toward term,
as infants mature during the ﬁrst few years of life, and as
children reach puberty and adolescence. Hence pediatric
population by itself is a spectrum of diﬀerent physiologies
and caters to diﬀerent subgroups by age, namely, preterm
neonates, full term neonates, infants and toddlers, and older
children and adolescents.
Themostnotablediﬀerencesindrugdispositionbetween
infants and children when compared with neonates and
young adults centre around alterations in body water and
serum protein composition [2].
Thereby a drug, unlike in an adult, is so very individual
child speciﬁc, speciﬁc to the growth and development.
Ignorance of this fact has caused adverse eﬀects, for example,
gray-baby syndrome caused by chloramphenicol.
Unfortunately, nowadays, 50–90% of drugs used in
children have never been actually studied in this population.
Prelicensure studies on safety and eﬃcacy of a drug are
generally carried out in adult subjects. In majority of times
their safety and tolerability are extrapolated from such adult
studies. The allometric methods used to calculate the dose
for a child taking into account diﬀerent categories of age,
the body weight, and/or the body surface area consider the
children as small adults, which is not the case [3].
3. The Ideal Children’s Medicine
WHO states that “The ideal children’s medicine is one that
suits the age, physiological condition, and body weight of
the child taking them and is available in a ﬂexible solid oral
dosage form that can be taken whole, dissolved in a variety of
liquids, or sprinkled on foods, making it easier for children
to take [4]”.2 International Journal of Pediatrics
4. RationalUse of Drugs
Rational use of drugs can be deﬁned as prescribing the right
drug, in adequate dose for the suﬃcient duration and appro-
priate to the clinical needs of the patients at lowest cost [5].
The following measures can help in promoting appropri-
ate and rational drugs in children.
4.1. Prescribing the Appropriate Medicines. All drugs have a
therapeutic range below which they do not work or above
which they are toxic. Drugs hence need to be used in the
utmost rational manner in the correct dosages for correct
duration. Though pediatrics is a well-recognized specialty,
majority of the children in the health care system are being
treated by family physicians who may not have received a
good formal training in this ﬁeld. This has led to wrong
diagnosis and misuse of antibiotics and other drugs.
4.1.1. Daily Practice Medicines. Most of the respiratory and
gastrointestinalinfectionsseeninday-to-dayclinicalpractice
are fortunately viral in origin and need only symptomatic
treatment. Paracetamol is the safest antipyretic. The Indian
medicalfraternityhaswokenuptotherampantuseofunsafe
antipyretics and cough cold medicines and was taken steps
to curb their usage. The latest examples are the ban of
drugs like nimesulide and phenylpropanolamine containing
anticold formulation, and so forth. The incidence of Reye’s
syndromehassigniﬁcantlyreduced,paralleltoreduceduseof
aspirin.ManyWesterncountriesliketheUSandtheUKhave
banned the use of cough-cold medicines for age below two
years because of reports of lethal sedation due to accidental
overdosage in this age group.
4.1.2. Antimicrobials. Antimicrobials need a special mention
due to the biggest threat of growing resistance to these
drugs. The main reason behind this potential medical
catastropheisoverzealousprescriptionofantimicrobialsthat
are not indicated, for example in many viral infections, using
inadequate dosage or duration of drug regime leading to
partially treated infections, using the wrong antimicrobial
due to ignorance of causative organisms, and ﬁnally using
indigenous, irrational combinations.
Antibioticsshouldbeprescribedasperthemostprobable
causative agent causing the diseases. It is preferable to choose
a single drug with the narrowest spectrum eﬀective for the
pathogen. Such a choice is likely to have the least toxicity,
least cost, the least danger of inducing drug resistance to
broad spectrum antibiotics, and the least chance of causing
superadded infection with resistant organisms. One also
needs to consider the eﬀect of drug on the target site, for
example the CSF permeability in case of meningitis.
While prescribing antibiotics, the host factors also need
to be considered. For example, tetracycline should be given
onlyabove7yearsofage.Drugdosagesneedtobeadjustedin
hepatic or renal dysfunction. A bactericidal drug is preferred
in an immunocompromised child.
Combination antibiotic therapy may be used if it pro-
vides synergy as in case of penicillin combination with an
aminoglycoside for treatment of S. viridans endocarditis; or
in polymicrobial infections like cerebral abscess, intraab-
dominal infections, and in prolonged courses given over
months, for example, tuberculosis, leprosy, HIV infection to
prevent emergence of drug resistant strains.
In situations where there is suspicion of infection
based on indirect evidences of infection like leucocytosis
(or leucopenia in neonates), acute phase reactants (like
CRP, Calcitonin, etc.), radiology (consolidation on X-ray),
and exudates (pleural ﬂuid, CSF, joint aspirates, abscesses,
etc.), antibiotics can be used empirically without awaiting
deﬁniteidentiﬁcationofthecausativeorganismaftersending
investigations aimed at making a microbiological diagnosis
(if available and feasible). It is particularly important to
send cultures diligently collected, before the ﬁrst dose of any
antibiotic is administered except in sick neonates or toxic
child where one cannot wait for culture reports and need to
start antibiotic urgently.
Patients requiring hospitalization for complicated or
seriouscommunityacquiredinfectionssuchastyphoidfever,
pneumonia, or dysentery should be treated with ﬁrst line
drugs based on local epidemiology and prevailing sensitivity
trends. It is best to use a single antibiotic. One may
ideally choose an antibiotic with both parenteral and oral
formulations so that the same antibiotic may be continued
orally after initial parenteral therapy, at the same time
keeping in mind that such a switch over, that is, sequential
parenteral to oral, is not recommended in some infections
like acute bacterial meningitis.
Children with chronic conditions, such as HIV/AIDS,
may have to take several medicines daily. For them, ﬁxed-
dose combination products with several medicines in one
pill are best. However, very few ﬁxed-dose combinations for
children exist.
Unfortunately several indigenous combinations have
ﬂooded the pharmaceutical market. The concern of these
combinations is that they have been launched without
adequate research into pharmacokinetic compatibility of the
partner drugs and clinical eﬃcacy. Examples of such drugs
arenorﬂoxacin,metronidazole,ceftriaxone,andtazobactam.
However intelligent man tries to become by inventing
the best possible diagnostic tools and drugs to com-
bat the microbes, it’s a head-to-head race where often
the microbes manage to develop some sort of mecha-
nism of resistance. And most of the time our loss to
these microbes can be attributed to the injudicious, irra-
tional, and overuse of antibiotics. The best examples are
the recent menace of extended-spectrum betalactamases
(ESBLs) and methicillin resistant staphylococcus aureus
(MRSA), and metallobetalactamases. overuse of 3rd gen-
eration cephalosporins has been implicated in increasing
proliferation of ESBL pathogens. Increasing number of
multidrug resistant typhoid, tuberculosis, and malaria cases
pose a nightmare for treating physicians.
4.2. Designing Better Pediatric Formulations. Diﬀerent for-
mulations are required for each subgroup which would
address the drug metabolism, compliance, timing of drug
administration, and reactions to drug use.International Journal of Pediatrics 3
Also, children are at a higher risk to develop adverse
reactions due to greater prevalence of multidrug therapy
as in the neonatal intensive care unit, or in children with
greater length of hospital stay as in children with congenital
or chronic diseases.
Due to nonavailability of appropriate pediatric formula-
tions,forexample,certainantituberculardrugs,antiepileptic
and the health care providers have to resort to administering
crushed tablets or dissolving in solvents, which can lead to
administration errors and sometimes interfere with bioavail-
ability. Lessons need to be learnt from the tragic incident
of 4 children under 36 months who died from choking
on albendazole tablets during a deworming campaign in
Ethiopia in 2007 [6]. WHO in December 2007 launched a
campaign called “Make medicines child size” which raised
awareness and stimulated action to improve the availability
of safe, eﬀective, and quality medicines for children.
4.3.MinimizingDrugAdministrationErrors. Duetotheneed
to calculate drug dosage on every pediatric patient based
on either the weight, body surface area, age, or their body
condition, there is high risk of medication errors, especially
with incorrect recordings of patients, weights and the
arithmetical calculations involved. Dosing errors of 10-fold
or greater can occur due to miscalculation of misplacement
of a decimal point. For example, at a crucial moment
of cardiac resuscitation adrenaline has to be administered
0.01mL/kg of 1:1000 dilution intramuscularly or 0.1mL/kg
of 1:10000 dilutions through intravenous route and a vise-
versa miscalculation can prove fatal.
Inspite of better devices like syringe pumps for accuracy
of dosage, drug errors may occur due to poor nursing
compliance with the pump speciﬁcations leading to either
poor response or an unexpected adverse reaction. It is not
uncommon misunderstand the prescription that parents
of drops versus syrup where sometimes, for example, as
in case paracetamol, the drops may contain ﬁve-times
higher concentration per mL compared to syrup, and wrong
interpretation can easily lead to drug overdose. In a review
in UK, over an eight-year period (1993 to 2000), there
were 81 medication-error incidents involving at least 1144
children. There were at least 29 deaths, nine of which
involved neonates. The most frequent type of medication
error involved an incorrect dose [7].
Therefore, the goal of a zero drug error rate should
be aggressively sought, with systems in place that aim to
eliminate the eﬀects of inevitable human error. This involves
review of the entire system from drug manufacture to drug
administration, not by ﬁnding fault in the individual, but by
identifying faults in the system and building into those sys-
tem mechanisms for picking up faults before they occur [8].
4.4. Minimizing Adverse Eﬀects. Children are often exposed
totheriskofadversedrugevents.Becausechildren,especially
the younger ones, are less articulate in describing symptoms,
and their nonverbal communication is often misunderstood
or ignored, even serious adverse reactions in children often
go unreported to health practitioners or authorities. All
countries should establish national and regional monitoring
systems for the detection of serious adverse medicine reac-
tions in children. When such reporting systems exist, it is
crucial that manufacturers follow up on adverse reactions to
their products once they are on the market.
4.5. Improving Drug Compliance. Taste, smell, color, consis-
tency, dosing frequency, and cost aﬀect patient compliance
with the drug regimen. Spitting of foul-tasting medications
is very common among infants and younger children. Com-
pliance should be improved with correct prescription of the
drugaswellascorrectcounselingofcaretakersadministering
the drug. The importance of proper counselling cannot be
overstated. However, inspite of prescribing the medicine in
the correct dose for the correct duration, the crying infant
may just spit out some amount of medicine while deﬁantly
accepting it. Therefore, in all practical sense, what fraction
of the prescribed medicine is really swallowed by the child
remains a mystery.
4.6. Making Drugs Available. Surveys conducted in over 40
low-income countries show that 44% of public sector and
65% of private sector outlets had the listed generic medicines
in stock. Lack of medicines in the public sector forces
patients to go without or purchase medicines from private
sector outlets where generic medicines cost on average 610%
more than their international reference price [9]. It is of
paramount importance that at least the essential pediatric
medicines are available in the public sector which caters to
majority of the population.
4.7. Educating Parents and Caretakers. Self-medication by
parents on advice of relatives or acquaintances, traditional
medicines, or any over-the-counter medicine unsupervised
byahealthprofessionalisrampantintheIndiancommunity,
for example, medicines to promote teething in infants. Some
medicines require reconstitution before oral use. Sometimes
thesemedicinesarewronglypreservedandusedbeyondtheir
expiry which is harmful.
4.8. Supervising Public Health Programs Involving Children.
In public health programs, comorbidity or malnutrition can
exacerbate toxicity. For example, dehydration is frequently
associated with ibuprofen-induced renal failure and mal-
nutrition with paracetamol hepatotoxicity. Hence vigilance
by the health authorities is required to check the clinical
eligibility and health priority of the child receiving the
medication. Also these programs should involve proper
training of health workers for correct administration of the
drugs to children.
4.9. Legalising Drug Related Issues by Health Authorities
4.9.1. Drug Regulatory Body in India. The Central Drug
Standards and Control Organization (CDSCO) is the prin-
cipal regulatory body, which functions under the Ministry of
Health and Family Welfare, government of India. It ensures
the approval, production, and marketing of quality drugs by
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(i) laying down the standard of drugs,
(ii) regulating market authorisation of new drugs and
clinical research,
(iii) approving licenses to manufacture certain categories
ofdrugsasCentralLicenceApprovingAuthority,that
is, large volume parenterals and vaccines and sera,
(iv) carrying out investigation and prosecution in respect
of contravention of legal provisions and regulating
the standards of imported drugs,
(v) pre- and post-licensing inspection, recalling of
substandard drugs, publication of Indian Pharma-
copoeia,
(vi) monitoring adverse drug reactions (ADR) and
screening periodically the drug formulations available in
Indian market.
4.9.2. Law Related to Spurious Drugs in India [10]. The
Drugs and Cosmetics (Amendment) Act, 2008, passed by
the Parliament on 5 December 2008 provides deterrent
penalties for oﬀences relating to manufacture of spurious
or adulterated drugs which have serious implications on
public health. The penalty for manufacture of spurious or
adulterateddrugshasbeenenhanc edtoanimprisonmentfor
a term which shall not be less than 10 years but which may
extendtoimprisonmentforlifeandshallalsobeliabletoﬁne
which shall not be less than ten lakh rupees or three-times
value of the drug conﬁscated, whichever is more. In certain
cases oﬀences have been made cognizable and nonfbailable.
Italsoprovidesatoolofcompoundingofoﬀencesfordealing
with certain minor oﬀences.
4.10. Curbing Lucrative Oﬀers from the Pharmaceutical Indus-
try. Incentive schemes for doctors and pharmacy staﬀ from
the pharmaceutical industry in the form of expensive gifts,
free travel and leisure trips, or travel and accommodation
arrangements prove a big hurdle in the prescription of
rational drug with speciﬁc request for encouragement of
their products. These practices need to be discouraged by the
law as small personal gains can lead to long-term adverse
eﬀect on the community like increased resistance due to
promotion of irrational drugs by such unethical doctors.
4.11. Educating the Doctors, Paramedical Staﬀ,a n dH e a l t h
Workers. Basic education in rational prescribing of drugs
rightfromtheundergraduateandpostgraduatetrainingdays
is very important for a clear foundation. Continued medical
education (CME), conferences, circulars, newsletters, e-
letters, and journals provide important source of informa-
tion to the practitioners for education and promotion of the
rational use of drugs.
5. Off-Label Drugs:Still a GrayArea
Oﬀ-label (unlabelled or unapproved) use of an approved
product refers to the use of an approved product in a
scenario that is not included or is disclaimed in the product
information. Studies throughout Europe have shown that at
least one third of children in hospitals and up to 90% of
neonates in a neonatal intensive care unit receive such drug
prescriptions. The medicines that are most frequently used
oﬀ label include analgesics, antibiotics, and bronchodilators
[11].
A study conducted to determine the extent and nature of
oﬀ-label drugs in pediatric ward of a tertiary health centre in
India found the oﬀ-label-drug use rate was 1.74 ± 1.56 per
patient. The maximum rate of oﬀ-label drugs was in infants
(2.33/patient). “Alteration in dosage” was by far the com-
monest reason for oﬀ-label use, followed by “age” and “indi-
cation.” Furosemide (i.v.), diazepam (i.v.), cefotaxime (i.v.),
ethambutol (tab), and prednisolone (tab) were the ﬁve com-
monest oﬀ-label drugs used in the study population [12].
Inspite of the rampant use of oﬀ-label drugs across the
world, researchers have not been able to identify whether
the use of oﬀ-label drugs in certain situations are ineﬀective,
unsafe, or may cause substantial beneﬁt to the patients [13].
The legal implications of using oﬀ- l a b e ld r u g sa r es t i l ln o t
clear.
6.WHOInitiatives
Promoting appropriate and safe drugs for children is a
global concern. In December 2007, WHO published its ﬁrst
ever model list of essential medicine list for children with
more than 200 medicines, including HIV/AIDS treatment,
vaccines, anesthetics, hormones, vitamins, and minerals.
This serves as a reference for countries to develop national
essential medicines lists, according to their speciﬁc public
healthneeds.Thelistisupdatedeverytwoyearsandhasbeen
recognized as a powerful tool to promote health equity. The
second edition was published in April 2010.
In India, the establishment of essential medicines lists
for children in two states, Orissa and Chhattisgarh, is
currently under way. The Indian Academy of Paediatrics is
also reviewing a list for implementation at a national level.
This will allow for better selection and procurement of child
medicines based on speciﬁc needs.
7.MoreResearchNeeded
Diﬀerences in therapeutic approaches in children are wide,
which implies the need for harmonization. A formulary is
required which, in addition to providing the therapeutic
function and dosage of the drug, can also be a source of
up-to-date and evidence-based information for the most
common clinical problems in and out of hospital. Since most
of the drugs have not been studied in this population, it
is important to have proper research trials. Unfortunately
children, especially in the underdeveloped countries, are
often victims of unethical clinical trials. Therefore, pediatric
research trials need to be conducted under governance of
strict laws and regulations.
8. Conclusion
There are enough clinical and scientiﬁc grounds to under-
stand the signiﬁcant diﬀerences in the pharmacologicalInternational Journal of Pediatrics 5
science between adults and children and not merely extrap-
olate the results from adult studies. It is of paramount
importance to strengthen the health system so that the
individual child’s medical need is both scientiﬁcally and
ethically addressed right from the drug manufacture to
its administration. Availability of properly labeled pediatric
formulations, regular audit by pharmacists, judicious pre-
scriptions, proper counseling about drug administration,
and surveillance of adverse eﬀects can save millions of
children.
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